2003
Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma
Sheryka E, Wheeler MA, Hausladen DA, Weiss RM. Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. Urology 2003, 62: 162-166. PMID: 12837459, DOI: 10.1016/s0090-4295(03)00134-1.Peer-Reviewed Original ResearchConceptsUrinary IL-8 levelsIL-8 levelsTransitional cell carcinomaBacille Calmette-GuérinIL-8Cell carcinomaCalmette-GuérinProstate cancerHealthy subjectsActive transitional cell carcinomaUrinary interleukin-8 levelsLow stage transitional cell carcinomaInterleukin-8 levelsBladder cancer cell linesBladder cancer cellsEnzyme-linked immunosorbentCancer cell linesIntravesical therapyInflammatory processInvasive tumorsAngiogenic factorsMitomycin CElevated levelsCancer cellsMitomycin C.Effect of Intravesical Treatment of Transitional Cell Carcinoma With Bacillus Calmette-Guerin and Mitomycin C on Urinary Survivin Levels and Outcome
HAUSLADEN DA, WHEELER MA, ALTIERI DC, COLBERG JW, WEISS RM. Effect of Intravesical Treatment of Transitional Cell Carcinoma With Bacillus Calmette-Guerin and Mitomycin C on Urinary Survivin Levels and Outcome. Journal Of Urology 2003, 170: 230-234. PMID: 12796695, DOI: 10.1097/01.ju.0000063685.29339.24.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntravesicalAgedAged, 80 and overAntibiotics, AntineoplasticAntigens, NeoplasmBCG VaccineBiomarkers, TumorCarcinoma, Transitional CellFemaleHumansImmunoblottingInhibitor of Apoptosis ProteinsMaleMicrotubule-Associated ProteinsMiddle AgedMitomycinNeoplasm ProteinsNeoplasm Recurrence, LocalPredictive Value of TestsPrognosisSurvivinTreatment OutcomeUrinary Bladder NeoplasmsConceptsTransitional cell carcinomaCompletion of treatmentBacillus Calmette-GuerinUrinary survivin levelsSurvivin levelsTCC recurrenceCalmette-GuerinUrine survivinIntravesical treatmentIntravesical instillationCell carcinomaMitomycin CRecurrent transitional cell carcinomaPrognostic molecular markersHigher survivin levelsUrinary survivinPosttreatment valuesRecurrenceMonthsHigher likelihoodSurvivinRemissionUrineTreatmentInstillation
1999
INDUCIBLE NITRIC OXIDE SYNTHASE WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER
SWANA H, SMITH S, PERROTTA P, SAITO N, WHEELER M, WEISS R. INDUCIBLE NITRIC OXIDE SYNTHASE WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER. Journal Of Urology 1999, 161: 630-634. PMID: 9915473, DOI: 10.1016/s0022-5347(01)61985-2.Peer-Reviewed Original ResearchConceptsTransitional cell carcinomaNitric oxide synthaseInducible nitric oxide synthaseReverse transcriptase-polymerase chain reactionBladder tissueCell carcinomaInflammatory cellsNOS activityOxide synthaseNitric oxideTumor cellsGrades of TCCDistribution of iNOSImmunoreactive iNOS proteinHuman bladder tumorsTranscriptase-polymerase chain reactionIndividual tumor cellsControl bladder tissueCytostatic mediatorsINOS antibodyTumor immunoreactivityWestern blot analysisBladder tumorsTumor gradeImmune stimulationINDUCIBLE NITRIC OXIDE SYNTHASE WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER
SWANA H, SMITH S, PERROTTA P, SAITO N, WHEELER M, WEISS R. INDUCIBLE NITRIC OXIDE SYNTHASE WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER. Journal Of Urology 1999, 161: 630-634.. DOI: 10.1097/00005392-199902000-00090.Peer-Reviewed Original ResearchTransitional cell carcinomaNitric oxide synthaseInducible nitric oxide synthaseReverse transcriptase-polymerase chain reactionBladder tissueCell carcinomaInflammatory cellsNOS activityOxide synthaseAbstract Purpose Nitric oxideNitric oxideTumor cellsGrades of TCCDistribution of iNOSImmunoreactive iNOS proteinPurpose Nitric oxideHuman bladder tumorsTranscriptase-polymerase chain reactionIndividual tumor cellsControl bladder tissueCytostatic mediatorsINOS antibodyTumor immunoreactivityWestern blot analysisBladder tumors
1973
Neoplasms of transitional cell origin in first twenty years of life
McGuire E, Weiss R, Baskin A. Neoplasms of transitional cell origin in first twenty years of life. Urology 1973, 1: 57-59. PMID: 4792287, DOI: 10.1016/0090-4295(73)90114-3.Peer-Reviewed Original Research